Amtolmetin guacil: is it possible to develop an "advanced" NSAID?

Медицинский совет

A. E. Karateyev¹ 

[1] Research Institute of Rheumatology named after V.A. Nasonova RAMS;

关键词: нестероидные противовоспалительные препараты;    доноры оксида азота;    толметин;    амтолметин гуацил;    гастропротективный эффект;    nonsteroidal anti-inflammatory drugs;    nitric oxide donors;    tolmetin;    amtolmetin guacil;    gastroprotective effect;   

DOI  :  10.21518/2079-701X-2013-12-84-89

来源: DOAJ

【 摘 要 】

NSAID is a key element in the treatment of acute pain and management of chronic pain. However, NSAIDs may cause serious complications in the gastrointestinal tract and the cardiovascular system. Pharmacologists have been trying to develop an "advanced" NSAID which does not affect the gastrointestinal tract, including coxibs, NSAIDs in combination with gastroprotective agents (misoprostol, H2 blockers, PPI), COX-2/LOX-2 inhibitors, and CINOD. All of these drugs have their limitations, some of them are being used, while others remained in the research phase or were ousted from clinical practice. Amtolmetin guacil is a new "advanced" NSAID based on the non-selective NSAID tolmetin, which posesses a number of gastroprotective attributes. It is specific for being able to increase the NO concentration in the gastrointestinal mucosa. The article describes the mechanism of action of the new drug, and shares the results of laboratory and clinical trials.

【 授权许可】

Unknown